Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkers
Blood Vessels, Thrombosis & Hemostasis · 2025-11 · 2 (4) · 100105
DOI: 10.1016/j.bvth.2025.100105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2025-11. Verfasst von Laura Simons und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Endothelial dysfunction contributes to mortality after cellular therapies, yet its clinical assessment remains challenging. In this prospective observational study, we evaluated 169 patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy and 102 healthy controls to determine whether a comprehensive endothelial profile, including the endothelial activation and stress index (EASIX), glycocalyx thickness (via sublingual GlycoCheck microscopy), digital perfusion (Tivita hyperspectral imaging), endothelial serum markers (angiopoietin-2, soluble thrombomodulin [CD141], chemokine (C-X-C motif) ligand 8, chemokine (C-X-C motif) ligand 9, interleukin-18, enzyme-linked immunosorbent assays), and platelet aggregation (flow cytometry), correlates with clinical outcomes. We observed significant intercorrelations among EASIX, perfused boundary region (PBR), tissue perfusion, and endothelial serum markers. Importantly, elevated EASIX, angiopoietin-2, impaired PBR, and reduced digital perfusion were significantly associated with early sepsis, whereas EASIX also independently predicted nonrelapse mortality. These findings highlight the heterogeneity of endothelial responses to systemic insult and reinforce the need for multimodal assessment in a larger study. EASIX, as a simple and routinely available marker, emerges as a valuable tool to stratify endothelial risk and guide monitoring in patients undergoing cellular therapy. This trial was registered at www.ClinicalTrials.gov as #NCT05502887.
Autor:innen und Institutionen
- Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Pediatric Oncology and Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Cardiology Department, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany.
- Division of Intelligent Medical Systems, German Cancer Research Center, Heidelberg, Germany.
- Faculty of Mathematics and Computer Science, Heidelberg University, Heidelberg, Germany.
Zitieren
APA
Simons, L., Alasfar, L., Qadoura, M., Buhl, J., Sunderer, F., Korell, F., Ikonomidis, I., Dietrich, M., Seidlitz, S., Vink, H., Maier-Hein, L., Schmitt, M., Schlenk, R. F., Carsten Müller-Tidow, Dreger, P., & Luft, T. (2025). Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkers. Blood Vessels, Thrombosis & Hemostasis, 2(4), 100105. https://doi.org/10.1016/j.bvth.2025.100105
Vancouver
Simons L, Alasfar L, Qadoura M, Buhl J, Sunderer F, Korell F, et al. Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkers. Blood Vessels, Thrombosis & Hemostasis. 2025;2(4):100105. doi:10.1016/j.bvth.2025.100105
BibTeX
@article{Simons2025,
author = {Simons, Laura and Alasfar, Lina and Qadoura, Muath and Buhl, Jule and Sunderer, Franziska and Korell, Felix and Ikonomidis, Ignatios and Dietrich, Maximilian and Seidlitz, Silvia and Vink, Hans and Maier-Hein, Lena and Schmitt, Michael and Schlenk, Richard F and Carsten Müller-Tidow and Dreger, Peter and Luft, Thomas},
title = {Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkers},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2025},
volume = {2},
number = {4},
pages = {100105},
doi = {10.1016/j.bvth.2025.100105}
}
EUVIMED